Shares of Cyclacel Pharmaceutical (CYCC -3.9%) slide after releasing updated survival data over...
Monday, December 10, 2012, 12:26 PM ETShares of Cyclacel Pharmaceutical (CYCC -3.9%) slide after releasing updated survival data over the weekend from its Phase III studies of its oral sapacitabine capsules, a treatement for elderly patients with newly diagnosed acute myeloid leukemia who are not candidates for chemotherapy. The data was presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles